FLG works with leading life sciences and healthcare companies, from seed stage to emerging to enterprise. These innovative players are highly focused around fundraising, dealmaking and carefully managing their costs. Rapidly evolving biotech, pharma and medtech clients are typically less focused on generating revenue but have significant regulatory and reporting requirements. These clients require continual fundraising through all phases of growth. Pharma clients also need to know their CFO understands the FDA’s approval path to commercial viability. And familiarity with some of the science behind a drug going to market and what constitutes the total available market for a drug are key. Managing a life science, pharma or medtech company successfully to exit, often through a strategic acquisition scenario, is also a critical skill set for a healthcare sector CFO.
Related Case Studies:
What Our Life Sciences Clients Say
“When I agreed to join Hansen Medical, I knew we faced a multitude of challenges that had to be promptly addressed. As we evaluated the capital needs and cost structure of the company, I needed a CFO who could be a balanced and trusted business partner. I needed someone to ensure my strategy was being implemented effectively, essentially an extension of me. Chris Lowe, my FLG partner, was immediately effective in guiding our financing strategy and implementing our cost reduction plans. The success of these programs allowed us to then pursue a strategic sale. Our achievements could not have been done without FLG’s support.”Cary Vance, CEO, Hansen Medical Inc.
“We were seeking consulting in our finance function for long-term planning, financing, and reporting. We hired Patrick Nugent at FLG and he couldn’t have been a better choice. Patrick was able to provide effective frameworks and best practices, leverage his network and expertise in the industry, and engage cross-functionally. As a CFO, you have lots of choices when you hire outside resources like we did at Mission Bio, but I would definitely recommend FLG for providing talent with strong strategic-thinking, expertise, thoroughness and the ability to engage as a true partner. I wouldn’t hesitate to hire from FLG Partners again for strategic support to our Finance team.”Marcel Roche, CFO, Mission Bio
“I’ve had the fortunate opportunity to work closely with Mark Murray of FLG Partners in a series of four successful venture backed -backed companies in Silicon Valley over the past dozen years including Optimedica Corporation (acquired by Abbott), Oculeve (acquired by Allergan), Oyster Point Pharmaceuticals (IPO) and most recently Kedalion Therapeutics (acquired by Novartis). I consider him to be the consummate professional and invaluable in providing state of the art financial management and strategic advising for young rapidly growing drug and medical device companies. Mark has a wealth of experience and considerable savvy in a variety of different situations and market conditions, whether it be in developing a strategic plan, raising capital, optimizing operations or helping identify and manage liquidity events. In my mind he is an absolute go-to thinker and do-er for any company looking to attract top level management talent.”
Mark S. Blumenkranz, CEO & Chairman, Kedalion Therapeutics